NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Taiwan Semiconductor
TSM
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
DCTH Delcath Systems
- 13.770
- +0.420+3.15%
Close Mar 4 16:00 ET
498.47MMarket Cap-11.77P/E (TTM)
14.120High12.620Low553.58KVolume13.040Open13.350Pre Close7.44MTurnover1.64%Turnover RatioLossP/E (Static)36.20MShares16.43052wk High58.10P/B465.84MFloat Cap2.25052wk Low--Dividend TTM33.83MShs Float7069.999Historical High--Div YieldTTM11.24%Amplitude-9223372036.855Historical Low13.440Avg Price1Lot Size
Delcath Systems Stock Forum
Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH) announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients. The study, conducted by researchers at Moffitt Cancer Center, compared Delcath's HEPZATO KIT™ to immunotherapy and other liver-directed therapies. Key findings include:
1. Overall Survival (OS): Median OS ...
Delcath Systems, Inc. Announces Promising Results From Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems (Nasdaq: DCTH) announced promising results from an independent study on its CHEMOSAT® Hepatic Delivery System for liver tumors. The study, conducted at the University Hospital of Leipzig, Germany, evaluated 33 patients with various cancers, including uveal melanoma and cholangiocarcinoma. Key findings include:
- A 91% diseas...
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
No comment yet